Global Ganja Report

The name most associated with cannabis science in the minds of aficionados is that of Israeli scientist Raphael Mechoulam—who is credited with first isolating and identifying THC. But given the current craze for CBD, there is another figure who should receive his due. The American chemist Roger Adams is the man who first isolated cannabidiol. And, by some accounts, he even has a claim to being the one who first identified its pyschoactive cousin THC.

In addition to this, he played a little-recognized role in the great world political upheavals of his time, as he grappled with the role of science—and its misuses—in war and totalitarianism.

Amid the seemingly endless hype about CBD, its once better-known sibling cannabinoid THC seems to increasingly languish in the shadows—both in terms of media attention and industry investment.

Voters in several states will cast ballots on cannabis-related measures in the Nov. 6 midterm election. Michigan and North Dakota are facing general legalization measures, while Utah and Missouri voters will get to weigh in on medical marijuana.

Justin Cooper is co-founder and CEO of British Columbia-based Green Planet, which supplies equipment to all of Canada's Licensed Producers of cannabis as well as producing its own line of fertilizers. He speaks with Cannabis Now about the fast-growing legal industry in his country, and what it means for the world.

The woman behind the South American nation's new medical marijuana law may yet face prison time. Her crime? Providing the only medicine that worked for her ailing son.

In the working-class Lima district of Pueblo Libre, I make my way to an apartment complex and up to the flat of Ana Álvarez—the unlikely woman almost singly responsible for Peru’s groundbreaking new medical marijuana law.

In a bedroom, 18-year-old Anthony watches a noisy Spiderman movie, occasionally interrupting through the open door as I chat with his mom in the living room. Anthony suffers from tuberous sclerosis, a severe form of epilepsy, and was the voiceless central figure behind the events that led to a major reform of Peru’s drug laws in 2017.

Last month, the DEA enthused the pharmaceutical industry but disappointed cannabis advocates by re-scheduling the drug Epidiolex—but not CBD, the cannabinoid that makes it work. Now word emerges of a letter to the DEA by the Food & Drug Administration essentially calling for the descheduling of CBD altogether.

Among several cannabis-related bills signed into law by California's Gov. Jerry Brown was one creating an "equity" program for the state's legalized industry. aimed at justice and inclusion for those communities hardest hit by marijuana prohibition. Another measure will erase past convictions for possession of cannabis in quantities that are now legal.

With the DEA's rescheduling of Epidiolex, shares in the British manufacturer of the drug are soaring. But CBD—the actual cannabinoid that the product is based on—is to remain in the restrictive Scheudle 1.